Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
44 hedge funds and large institutions have $64.1M invested in Esperion Therapeutics in 2013 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1,950% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 2
780% more funds holding
Funds holding: 5 → 44 (+39)
432% more capital invested
Capital invested by funds: $12M → $64.1M (+$52M)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$9.74M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.28M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$7.24M |
| 4 |
Morgan Stanley
New York
|
+$3.23M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
-$1.02M |
| 2 |
WHI
William Harris Investors
Chicago,
Illinois
|
-$916K |
| 3 |
MCM
Mazama Capital Management
Portland,
Oregon
|
-$823K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$59K |
ESPR Hedge Fund Activity: Q3 2013 in Review
44 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2013, worth a combined $64.1M — up 432% from $12M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ESPR positions and 2 closed out — a net gain of 39 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $9.74M. The largest seller was Levin Capital Strategies, exiting entirely with an estimated $1.02M sold.
- 44 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2013, up from 5 in Q2 2013.
- Funds reported $64.1M of Esperion Therapeutics stock for Q3 2013, up 432% quarter-over-quarter.
- 41 funds opened new Esperion Therapeutics positions in Q3 2013 and 2 closed out, a net change of +39 holders.
- The largest Esperion Therapeutics buyer in Q3 2013 was Polar Capital, an estimated $9.74M added.
- The largest Esperion Therapeutics seller in Q3 2013 was Levin Capital Strategies, an estimated $1.02M sold.
Based on aggregated 13F filings for Q3 2013.